Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis

Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study

(2018) MaryAnn Zhang et al.   CIRCULATION

Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions

(2018) Chuang-Wei Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

(2018) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions

(2017) Ching-Hua Ke et al.   JOURNAL OF RHEUMATOLOGY

Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis

(2017) Tony Zhang et al.   RHEUMATOLOGY

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

(2017) Catrin O. Plumpton et al.   RHEUMATOLOGY

Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions

(2016) Chuang-Wei Wang et al.   Current Opinion in Allergy and Clinical Immunology

Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment

(2016) Thomas Bardin et al.   JOINT BONE SPINE

Severe cutaneous adverse drug reactions

(2016) Wen-Hung Chung et al.   JOURNAL OF DERMATOLOGY

Impact of the HLA-B * 58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions

(2016) Chau Yee Ng et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study

(2015) Seoyoung C. Kim et al.   AMERICAN JOURNAL OF MEDICINE

Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions

(2015) Wen-Hung Chung et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Allopurinol Use and Risk of Fatal Hypersensitivity Reactions

(2015) Chien-Yi Yang et al.   JAMA Internal Medicine

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin

(2014) Wen-Hung Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout

(2014) George Nuki   CURRENT OPINION IN RHEUMATOLOGY

Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population

(2014) Surasak Saokaew et al.   PLoS One

An Allopurinol-Controlled, Randomized, Double-Dummy, Double-Blind, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan

(2012) Naoyuki Kamatani et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Febuxostat Hypersensitivity

(2012) A. M. ABELES   JOURNAL OF RHEUMATOLOGY

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

(2012) Dinesh Khanna et al.   ARTHRITIS CARE & RESEARCH

The DRESS Syndrome: A Literature Review

(2011) Patrice Cacoub et al.   AMERICAN JOURNAL OF MEDICINE

Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis

(2011) Ratchadaporn Somkrua et al.   BMC Medical Genetics

Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib

(2011) M. Back et al.   EUROPEAN HEART JOURNAL

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans

(2011) Hye-Ryun Kang et al.   Pharmacogenetics and Genomics

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

(2010) B Sassolas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout

(2010) E. Krishnan   RHEUMATOLOGY

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

(2010) Michael A Becker et al.   ARTHRITIS RESEARCH & THERAPY

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

(2009) Wichittra Tassaneeyakul et al.   Pharmacogenetics and Genomics

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial

(2008) H. RALPH Schumacher et al.   ARTHRITIS AND RHEUMATISM

A European study of HLA-B in Stevens???Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

(2008) Christine Lonjou et al.   Pharmacogenetics and Genomics

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis

(2008) Nahoko Kaniwa et al.   PHARMACOGENOMICS

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

(2007) Sima Halevy et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY